Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (4): 444-448.doi: 10.12092/j.issn.1009-2501.2021.04.012

Previous Articles     Next Articles

Research progress of melatonin on pulmonary hypertension

WANG Rui 1,2,3, PAN Jinjin 1, LI Hua 3, YUAN Yuhui 1   

  1. 1 Institute of Cancer Stem Cell, Dalian Medical University University, Dalian 116044, Liaoning, China; 2 Department of Hematology, the Second Hospital of Dalian Medical University, Dalian 116027, Liaoning, China; 3 College of Pharmacy, Dalian Medical University, Dalian 116044, Liaoning, China
  • Received:2020-11-30 Revised:2021-01-04 Online:2021-04-26 Published:2021-05-11

Abstract: Pulmonary hypertension is a severe disease with a wide spectrum of underlying etiologies, which was characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, and eventually leads to right heart dysfunction and even death with a high mortality rate. Melatonin, as a neuroendocrine hormone, is produced primarily by the pineal gland. Melatonin, a pleotropic molecule, plays a key role in the pathophysiology of various cardiovascular diseases.The effects of melatonin which can attenuate pulmonary vascular remodeling and pulmonary artery pressure have been widely concerned by researchers in recent years. This review summarized the progress of melatonin on pulmonary hypertension.

Key words: melatonin, pulmonary hypertension, anti-inflammation, anti-oxidation

CLC Number: